Published ahead of print on July 31, 2003, doi:10.1164/rccm.200302-200OC
© 2003 American Thoracic Society
Lung Deposition and Systemic Availability of Fluticasone Diskus and Budesonide Turbuhaler in ChildrenUniversity of Southern Denmark; and Department of Paediatrics, Kolding Hospital, Kolding, Denmark Correspondence and requests for reprints should be addressed to Lone Agertoft, Department of Paediatrics, Kolding Hospital, DK-6000 Kolding, Denmark. E-mail: lone_agertoft{at}dadlnet.dk Pharmacokinetic studies can be used to measure lung dose of inhaled drugs. The aim of this study was to compare the lung deposition of budesonide (BUD) inhaled from Turbuhaler (AstraZeneca, Lund, Sweden) and fluticasone propionate (FP) inhaled from Diskus (GlaxoSmithKline, London, UK) and to assess if the study design used for pharmacokinetic studies can be simplified. Plasma levels of BUD and FP were measured for 21 hours on five separate days in 15 patients aged 8 to 14 years: (1) Intravenous infusion of 200 µg BUD, (2) intravenous infusion of 200 µg fluticasone dipropionate, (3) inhalation of 800 µg BUD via Turbuhaler, (4) inhalation of 750 µg FP via Diskus, and (5) inhalation of BUD and FP on the same day. Charcoal was ingested to eliminate drug uptake from the gastrointestinal tract. The mean lung deposition of drug after Turbuhaler and Diskus inhalation was 30.8 and 8.0% when BUD and fluticasone were administered on separate days and 29.5% (BUD) and 7.6% (fluticasone) when the two drugs were inhaled on the same day. Lung deposition is four times higher in children after inhalation from Turbuhaler than after inhalation from Diskus. Pharmacokinetic studies with BUD and FP can be simplified because the two treatments can be administered on the same day.
Key Words: lung deposition • pharmacokinetics • inhaled corticosteroids • study design • children This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
